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Abstract
Background:  The nasal tissue uptake and metabolism of ciclesonide, a new-generation
corticosteroid under investigation for treatment of allergic rhinitis, to its active metabolite,
desisobutyryl-ciclesonide (des-CIC), was evaluated when administered to rabbits in a hypotonic
versus an isotonic ciclesonide suspension. Nasal mucosa extracts from normal Japanese white
rabbits were evaluated by high-performance liquid chromatography with tandem mass
spectrometry detection after a single 143-μg dose of ciclesonide. Retention and formation of fatty
acid conjugates of des-CIC were also measured in nasal mucosa extracts postadministration of a
hypotonic ciclesonide suspension (143-μg single dose).
Results: Versus an isotonic suspension, the hypotonic suspension achieved higher concentrations
of des-CIC (5.6-fold, 11.4-fold, and 13.4-fold; p < 0.05 for all) and ciclesonide (25.3-fold, 34.2-fold
[p  = not significant], and 16-fold [p  < 0.05]) at 30, 120, and 240 min postadministration.
Additionally, when administered via a hypotonic suspension, des-CIC was retained up to 24 h
postadministration (45.46 pmol/g tissue). Highest concentration of major fatty acid ester conjugate,
des-CIC-oleate, was detected in nasal mucosa at 8 h postadministration.
Conclusion:  These data suggest that a hypotonic ciclesonide suspension provides higher
intracellular concentrations of des-CIC up to 24 h, thereby providing a rationale for investigation
of ciclesonide as a convenient once-daily nasal spray for treatment of allergic rhinitis.
Background
Allergic rhinitis (AR) affects 10% to 30% of the world's
population and an estimated 20 to 40 million people in
the United States alone ([1-3]. Common symptoms of AR
include sneezing, itching, rhinorrhea, and nasal conges-
tion. According to the Allergic Rhinitis and Its Impact on
Asthma guidelines, AR is a major chronic respiratory dis-
ease that is increasing in prevalence; reduces quality of
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life, performance, and productivity; and is a significant
risk factor for asthma [4,5]. Current pharmacologic treat-
ments for AR include antihistamines, decongestants, and
intranasal corticosteroids (INS)[6]. Intranasal corticoster-
oids are recommended first-line medications in patients
with moderate or severe AR and provide effective relief of
nasal symptoms and congestion because of their potent
anti-inflammatory activity [6-8].
Ciclesonide is a new-generation corticosteroid currently
used for the treatment of asthma and has been approved
for the treatment of AR [9-11]. Ciclesonide is adminis-
tered as an inactive parent compound and is activated by
esterases to a pharmacologically active metabolite,
desisobutyryl-ciclesonide (des-CIC; Fig. 1) [12]. Esterifica-
tion of des-CIC at the carbon-21 position produces revers-
ible lipid conjugates of des-CIC that represent a pool of
active drug available for sustained long-term anti-inflam-
matory activity [13]. Studies with ciclesonide in normal
human bronchial epithelial cells and rat lung tissue and
budesonide formulations used for treatment of AR in
human nasal tissue have confirmed the role of fatty acid
conjugates in prolonged retention of these drugs [13-15].
The efficacy, safety, and tolerability of INS are affected in
part by the formulation of the suspension. Intranasal cor-
ticosteroids are usually formulated and administered via
an isotonic medium [16-18] However, ciclesonide is for-
mulated in a hypotonic suspension. The viscous consist-
ency of the hypotonic suspension provides longer
retardation of ciclesonide on nasal mucosa and a high
local concentration of ciclesonide to increase its absorp-
tion into nasal mucosa [19]. This may lead to enhanced
uptake of ciclesonide in nasal mucosa and higher local tis-
sue concentrations of des-CIC compared with traditional
isotonic INS suspensions, theoretically decreasing sys-
temic availability.
Formulation differences exist between INS based on the
type of preservative used [20,22]. Unlike other INS that
usually contain benzalkonium chloride as the preferred
preservative agent [20,21], ciclesonide hypotonic suspen-
sion is formulated for intranasal use with potassium sorb-
ate as the preservative agent [22].
The major aim of these preclinical studies in rabbits was
to compare the metabolism of ciclesonide to its active
metabolite, des-CIC, after intranasal administration as a
hypotonic or isotonic suspension and to investigate the
retention of ciclesonide and des-CIC and nasal mucosal
formation of fatty acid conjugates of des-CIC up to 24 h
after intranasal administration of a hypotonic suspension
of ciclesonide. Ciclesonide and des-CIC were analyzed in
homogenates prepared from the nasal mucosal tissue
using liquid chromatography with tandem mass spec-
trometry. A comparative analysis of data obtained from
rabbit nasal mucosa after intranasal administration of
hypotonic or isotonic suspension is reported herein.
Results
Ciclesonide uptake and formation of des-CIC in rabbit 
nasal mucosa
Mean nasal mucosal concentration of des-CIC was signif-
icantly higher after administration of the hypotonic sus-
pension compared with the isotonic suspension at all
time points 5.6-fold, 11.4-fold, and 13.4-fold higher at
30, 120, and 240 min, respectively, after administration; p
< 0.05 for all; Table 1; Fig. 2). Ciclesonide levels were
measurable in all the nasal mucosa samples only at 30
min after administration of isotonic suspension. How-
ever, 1 and 2 of the 4 samples were below the lower limit
of quantification at 120 and 240 min, respectively. By
contrast, when administered in hypotonic suspension,
ciclesonide was measurable in the nasal mucosa at all
time points (Table 2). The concentration of ciclesonide
was 25.3-fold higher at 30 min and 34.2-fold higher at
120 min after administration of the hypotonic suspension
compared with the isotonic suspension (p = not signifi-
cant). Moreover, the concentration of ciclesonide was sig-
nificantly higher at 240 min (16-fold) after
administration of the hypotonic suspension compared
with the isotonic suspension (p < 0.05).
Concentration-time profile of des-CIC in nasal mucosa
The concentration-time profiles of des-CIC in nasal
mucosa in the hypotonic and isotonic suspensions were
distinctly different. For the hypotonic ciclesonide suspen-
sion, a relatively high amount of des-CIC (215.2 pmol/g
tissue, 2.7-fold lower) was detected in the nasal mucosa
240 min after administration compared with 30 min (575
pmol/g tissue) after administration (Table 2). In contrast,
when administered in isotonic suspension, a negligible
amount of des-CIC (16 pmol/g tissue, 6.5-fold lower) was
detected in the nasal mucosa 240 min after administra-
tion compared with 30 min (102 pmol/g tissue) after
administration.
Retention of des-CIC and des-CIC fatty acid conjugates in 
rabbit nasal mucosa
Desisobutyryl-ciclesonide was measurable in the nasal
mucosa at all time points up to 24 h (45.46 pmol/g tissue)
after administration of a hypotonic suspension of cicleso-
nide (Fig. 3). The highest concentration of des-CIC (415
pmol/g tissue) was detected in the nasal mucosa as early
as 0.5 h after administration of ciclesonide, suggesting
that ciclesonide is rapidly converted to the active metabo-
lite. Desisobutyryl-ciclesonide-oleate and des-CIC-palmi-
tate were measurable in the nasal mucosa at all time
points up to 24 h after administration of ciclesonide.
Desisobutyryl-ciclesonide-oleate was the major fatty acidBMC Pharmacology 2007, 7:7 http://www.biomedcentral.com/1471-2210/7/7
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conjugate formed in the nasal mucosa, and the highest
concentrations of des-CIC-oleate (167 pmol/g tissue) and
des-CIC-palmitate (3.05 pmol/g tissue) were detected in
the nasal mucosa 8 h and 16 h, respectively, after admin-
istration of a hypotonic ciclesonide suspension.
Discussion
The intracellular localization and sustained concentration
of INS are dependent to varying levels on nasal mucosal
absorption, drug lipophilicity, glucocorticoid receptor
affinity, and the ability to form lipid conjugates in nasal
epithelial cells [23]. Retention and formation of fatty acid
conjugates of INS in human nasal tissue and its impor-
tance in treatment of AR have been reported [15,24]. In
the present study, the in vivo uptake and activation of
ciclesonide in a hypotonic suspension have been shown
to be superior to ciclesonide's uptake and activation in an
isotonic suspension. Furthermore, it has also been shown
that des-CIC and fatty acid conjugates of des-CIC are
present in rabbit nasal mucosa up to 24 h after adminis-
tration of ciclesonide in a hypotonic suspension.
Nasal mucosal concentrations of ciclesonide were numer-
ically higher after administration of a hypotonic suspen-
sion compared with an isotonic suspension and decreased
after 240 min of administration. The presence of relatively
higher amounts of ciclesonide versus des-CIC 120 min
after administration of the hypotonic suspension may be
explained by better absorption of ciclesonide in hypot-
onic medium. The presence of relatively smaller amounts
of ciclesonide (232.5 pmol/g tissue) at 30 min after
administration of the isotonic suspension suggests slow
uptake of ciclesonide when administered in isotonic sus-
pension. However, the nasal mucosal concentrations of
des-CIC were significantly and consistently higher 240
min after administration of a hypotonic suspension.
There is limited data available on the influence of tonicity
on nasal uptake [25,26]and tonicity is unlikely to have
any effect on particle size distribution. However, previous
studies in other systems have demonstrated that hypot-
onic formulations promote significantly greater absorp-
tion of water and sodium in the intestine [27,28].
The presence of des-CIC in nasal mucosa as early as 30
min after administration of hypotonic suspension sug-
gests rapid conversion of ciclesonide. The identification of
esterases present in nasal tissue is currently being investi-
gated in human nasal epithelial cells; although intracellu-
lar esterases are highly conserved across the species, it
would not be surprising to see minor differences in
human nasal mucosa. Preliminary evidence suggests that
carboxylesterases and cholinesterases are involved in the
metabolism of ciclesonide to des-CIC in human nasal epi-
thelial cells [29].
Our subsequent experiment with hypotonic suspension
in rabbit nasal mucosa further corroborated the evidence
of metabolism of ciclesonide and confirmed that des-CIC
is retained in nasal mucosa for 24 h after a single-dose
administration. This study also confirmed the formation
of des-CIC-oleate and des-CIC-palmitate conjugates of
des-CIC in nasal mucosa, reaching their highest levels 8 h
and 16 h postadministration, respectively. The presence of
fatty acid conjugates of des-CIC suggests that the active
drug may be retained in the nasal mucosa as a reversible
pool to exert sustained drug effects over time and allow
once-daily dosing. Similar metabolism of ciclesonide to
des-CIC in normal human bronchial epithelial cells and
rat lung tissue [14] and the presence of des-CIC-oleate and
des-CIC-palmitate fatty acid conjugates of des-CIC for a
Bioactivation of ciclesonide to the active metabolite,  desisobutyryl-ciclesonide (des-CIC), and formation of fatty  acid esters of des-CIC Figure 1
Bioactivation of ciclesonide to the active metabolite, 
desisobutyryl-ciclesonide (des-CIC), and formation of fatty 
acid esters of des-CIC.
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Table 1: Administration of hypotonic and isotonic ciclesonide suspensions and nasal tissue sampling.
Suspension administered Animals, n * Dose per animal, μg Volume per actuation, μL Sampling time, h
Hypotonic ciclesonide 4 143 100 0.5, 2, 4
Isotonic ciclesonide 4 143 100 0.5, 2, 4
Hypotonic ciclesonide 5 143 100 0.5, 8, 12, 16, 24
* = Represents the number of animals per sampling time.BMC Pharmacology 2007, 7:7 http://www.biomedcentral.com/1471-2210/7/7
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longer period of time have also been demonstrated in rat
lung tissue [13,30]. Fatty acid conjugation has also been
reported for budesonide in lung and nasal tissue [24,31].
However, des-CIC-oleate is 5-fold more lipophilic than
budesonide-oleate [32].
The hypotonic ciclesonide suspension containing the avi-
cel matrix used in this study diffuses rapidly into nasal
mucosa because of a difference in osmolarity between the
suspension and the nasal mucosa [19]. Diffusion of water
and subsequent loss of water into the nasal mucosa lead
to increased viscosity of the suspending agent and higher
adherence to nasal mucosa. This higher adherence of the
suspending agent leads to rapid accumulation of cicleso-
nide in the nasal mucosa and probable delayed clearance
of ciclesonide (Fig. 4). We hypothesize that initial conver-
sion of ciclesonide to des-CIC occurs almost instantane-
ously, whereas the subsequent conversion of des-CIC to
des-CIC-oleate and des-CIC-palmitate occurs slowly. The-
oretically, the interconversion of des-CIC from the fatty
acid conjugates may lead to relatively higher concentra-
tions of des-CIC within nasal mucosa for a longer period
of time.
Conclusions
The results of this study confirm that a hypotonic cicleso-
nide suspension provides better absorption and results in
higher cellular levels of ciclesonide and its active metabo-
lite, des-CIC, in nasal mucosa compared with an isotonic
ciclesonide suspension. The presence of des-CIC and fatty
acid conjugates of des-CIC in the rabbit nasal mucosa up
to 24 h after a single administration provides a rationale
for the investigation of ciclesonide nasal spray adminis-
tered via a convenient once-daily dosing regimen for the
treatment of AR.
Methods
This is a combined presentation of 2 related studies. The
first was a comparison of hypotonic and isotonic suspen-
sions of ciclesonide and will be referred to as the "compar-
ison" study. The second was a further evaluation of the
ability of des-CIC to form fatty acid conjugates in nasal
mucosa when ciclesonide is administered in hypotonic
suspension. The duration of fatty acids and des-CIC reten-
tion was also evaluated, and herein this study is referred
to as the "retention" study.
Materials
Ciclesonide, des-CIC, deuterated des-CIC, des-CIC-oleate,
and des-CIC-palmitate were supplied by ALTANA Pharma
AG (formerly Byk Gulden, Konstanz, Germany). Hypot-
onic and isotonic ciclesonide suspensions containing the
avicel matrix were supplied by Teijin Institute for Biomed-
ical Research, Teijin Pharma Limited, Tokyo, Japan (for-
merly Teijin Limited, Tokyo, Japan). Differences between
the 2 formulations were based on osmolarity of glucose
and the viscosity of microcrystalline cellulose (Table 3).
Concentrations of ciclesonide and desisobutyryl-ciclesonide  (des-CIC) in rabbit nasal mucosa after single-dose adminis- tration of a hypotonic ciclesonide suspension Figure 2
Concentrations of ciclesonide and desisobutyryl-ciclesonide 
(des-CIC) in rabbit nasal mucosa after single-dose adminis-
tration of a hypotonic ciclesonide suspension. Bars represent 
mean concentration ± standard deviation.
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Table 2: Concentrations of ciclesonide and des-CIC in rabbit nasal mucosa.
Time, min Ciclesonide pmol/g tissue * p value ** des-CIC pmol/g tissue * p value **
Hypotonic suspension
30 5884 ± 3982 NS 575 ± 276.3 < 0.05
120 2835 ± 2118 NS 366 ± 207 < 0.05
240 212.5 ± 102.1 < 0.05 215.2 ± 112.2 < 0.05
Isotonic suspension
30 232.3 ± 46.3 - 102 ± 32.1 -
120 83 ± 69.1 - 32 ± 25 -
240 13.3 ± 16.4 - 16 ± 20.3 -
des-CIC = desisobutyryl-ciclesonide; NS = not significant.
* = Data are mean ± standard deviation.
** = Versus isotonic suspension.BMC Pharmacology 2007, 7:7 http://www.biomedcentral.com/1471-2210/7/7
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Animals
Male (specific pathogen free) Japanese white rabbits, 16
to 17 weeks old, 2.5 to 3.1 kg weight were supplied by
Japan SLC Inc. (Shizuoka, Japan). Animals were individu-
ally housed in cages (AM-2612-03, Animec, Tokyo,
Japan), and water was provided ad libitum. Solid feed
(LRC4, Oriental Yeast Co., Ltd., Tokyo, Japan, for the
retention study and CR-3, Japan CLEA Inc., Tokyo, Japan,
for the comparison study) for rabbits was provided ad libi-
tum. The temperature in the room was 24 ± 2°C, and the
relative humidity was 55% ± 5% for the comparison
study. The temperature in the room was 24 ± 2°C, and the
relative humidity was 55% ± 15% for the retention study.
The animal-room lighting followed a 12-h light/dark
cycle. Animals were 17 weeks old at the time of adminis-
tration of hypotonic or isotonic ciclesonide suspensions
or were 19 weeks old at the time of the retention study.
The guidelines established by the ethical committee for
animal experiments of the Teijin Institute for Biomedical
Research were followed for care and use of animals.
Study design
All studies were performed at the Teijin Institute for Bio-
medical Research. Hypotonic and isotonic ciclesonide
suspensions were administered intranasally using a nasal
actuator (Flunase® Nasal Solution50, approved in Japan;
GlaxoSmithKline K.K., Tokyo, Japan; Table 3). One-hun-
dred microliters of the suspension was applied to each
nostril to obtain consistent saturation of the nasal
mucosa.
Tissue sampling
In the comparison study, at prescribed time points after
intranasal administration of hypotonic and isotonic cicle-
sonide suspensions (Table 1), nostrils were washed 3
times with 5 mL of physiological saline. Animals were
anesthetized with pentobarbital sodium and exsanguin-
ated from the carotid artery. Nasal mucosa including ven-
tral nasal concha, middle nasal meatus, choana, and
olfactory mucosal were immediately removed, weighed,
suspended in 4-fold volume of ice-cold ethanol of the wet
weight, minced, and homogenized. One milliliter of the
resultant homogenate was mixed with 25 μL of deute-
rium-labeled des-CIC internal standard solution (2 μg/
mL) in ethanol, vortex-mixed, and centrifuged at 1660 × g
for 15 min at 4°C. The extracted supernatant was stored at
-20°C until further analysis.
In the retention study, at prescribed time points after
intranasal administration of ciclesonide in a hypotonic
suspension (Table 3), animals were anesthetized with
33% (w/v) urethane aqueous solution containing 0.83%
(w/v)  α-chloralose and were exsanguinated from the
abdominal aorta. Immediately thereafter, the inside of the
nasal cavity was washed 5 times with 30 mL of physio-
logic saline containing 600 μmol/L phenylmethyl sulfo-
nyl fluoride (a serine protease inhibitor) using a cannula.
Nasal mucosa, including the nasal septum; ventral, mid-
dle, and dorsal nasal meatus and concha; and internal
nasal concha was immediately removed. Wet weight of
nasal mucosa was determined and was frozen in liquid
nitrogen and stored at -20°C until further analysis. For
extraction, nasal mucosa was minced in 4-fold volume of
ice-cold ethanol and homogenized. The homogenate was
centrifuged at 2620 × g for 15 min at 4°C, and 0.5 mL
aliquots of the supernatant were dispensed in Eppendorf
tubes and stored at -20°C. Seventy-five microliters of each
nasal tissue extract solution was combined with 25 μL of
deuterated des-CIC internal standard solution (100 ng/
mL), and the resultant mixture was used for analyses.
Analysis by liquid chromatography with tandem mass 
spectrometry (LC/MS/MS)
For the comparison study, 100 μL of purified water was
added to 100 μL of the extracted supernatant and vortex-
mixed. The samples were then transferred to 0.45 μm
membrane filters (Ultrafree-MC, Millipore Corporation,
Billerica, Massachusetts) and were centrifuged at 840 × g
for 3 min. The filtered samples were then transferred to
injection vials and measured by LC/MS/MS. Ciclesonide
and des-CIC were separated by high-performance liquid
chromatography (Agilent HP1100, Agilent Technologies,
Tokyo, Japan) using a CAPCELL PAK UG120, C18 (3 μm,
2 × 50 mm ID) column (Shiseido Company Limited,
Tokyo, Japan) with a mobile phase consisting of 65% (v/
v) acetonitrile/ethanol (4:1 ratio) and 35% (v/v) 5 mmol/
L ammonium acetate solution at a flow rate of 250 μL/
min. Calibration standards contained ciclesonide, des-
CIC, and deuterated des-CIC (analytes: ciclesonide and
Concentrations of ciclesonide, desisobutyryl-ciclesonide  (des-CIC), and fatty acid conjugates of des-CIC in rabbit  nasal mucosa after single-dose administration of a hypotonic  ciclesonide suspension Figure 3
Concentrations of ciclesonide, desisobutyryl-ciclesonide 
(des-CIC), and fatty acid conjugates of des-CIC in rabbit 
nasal mucosa after single-dose administration of a hypotonic 
ciclesonide suspension. Values represent mean concentration 
± standard deviation.
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des-CIC; internal standard: deuterated des-CIC, range 0.5
ng/mL to 1 μg/mL). The lower limits of quantification
were 1.0 and 0.5 ng/mL for ciclesonide and des-CIC,
respectively. Ciclesonide and des-CIC were detected by
turbo ion spray MS/MS (API3000, Applied Biosystems,
Tokyo, Japan) with negative polarity and multiple reac-
tion monitoring scan mode.
The hypothetical mechanism of the intranasal uptake of hypotonic or isotonic suspensions of ciclesonide Figure 4
The hypothetical mechanism of the intranasal uptake of hypotonic or isotonic suspensions of ciclesonide. des-CIC, desisobu-
tyryl-ciclesonide.
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Administration of Formulation Into Nose
•  Longer retardation of ciclesonide on nasal mucosa
•  High local ciclesonide concentration 
  to increase its absorption into mucosal tissue
•  Increased des-CIC in mucosal tissue
•  Rapid clearance into esophagus with drug diffusion
•  Insufficient ciclesonide absorption into nasal mucosa 
•  Lower concentration of ciclesonide 
  and des-CIC in mucosal tissue
Table 3: Composition of hypotonic and isotonic formulations of ciclesonide.
Composition, % weight Hypotonic Isotonic
Crystalline cellulose/Carmellose sodium 1.7 1.7
Ciclesonide 0.0714 0.0714
HPMC 0.1 0.1
Glucose 4.75 -
pH 4.53 4.54
Viscosity (mPa/s) 94 76
Osmolality (mOsm) 324 33
HPMC = Hydroxypropyl methylcellulose.BMC Pharmacology 2007, 7:7 http://www.biomedcentral.com/1471-2210/7/7
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For the retention study, concentrations of ciclesonide,
des-CIC, and fatty acid conjugates (des-CIC-oleate and
des-CIC-palmitate) in the supernatants from nasal
mucosal homogenates were analyzed by LC/MS/MS.
Ciclesonide, des-CIC, and des-CIC fatty acid conjugates
were separated by high-performance liquid chromatogra-
phy (Agilent, HP1100) using a Hypersil® Phenyl2 (5 μm,
4.6 × 50 mm ID) column (Thermo Electron, K. K., Yoko-
hama, Japan) with a mobile phase consisting of 95% (v/
v) acetonitrile/1 mmol/L ammonium acetate solution
and 25% (v/v) acetonitrile/1 mmol/L ammonium acetate
solution at a flow rate of 1 mL/min for a total run time of
7 min. Calibration standards contained ciclesonide, des-
CIC, des-CIC-oleate, des-CIC-palmitate, and deuterated
des-CIC (analytes: ciclesonide, des-CIC-oleate, and des-
CIC-palmitate; internal standard: deuterated des-CIC,
range 0.1 to 20 ng/mL, and des-CIC, range 0.2 to 40 ng/
mL). The lower limits of quantification were 0.1 ng/mL
for ciclesonide, 0.2 ng/mL for des-CIC, and 0.10 ng/mL
for both des-CIC-oleate and des-CIC-palmitate, respec-
tively. Ciclesonide and its metabolites were detected by
turbo ion spray MS/MS (API3000, Applied Biosystems,
Tokyo, Japan) with negative polarity and multiple reac-
tion monitoring scan mode. Molecular weights of cicleso-
nide, des-CIC, des-CIC-oleate, and des-CIC-palmitate are
540.7, 470.6, 735.1, and 709.0 g/mol, respectively.
Data analysis
Calibration curves were prepared by the linear least
squares method using the peak area ratios of the internal
standard solutions. Concentrations of analytes in the sam-
ples were calculated by substituting the peak area ratios
determined by a quantitative analysis versus the calibra-
tion curve. Data were calculated as the concentration of
analytes versus unit nasal mucosal weight after converting
concentration (ng/mL) to corresponding molar concen-
trations and expressed as mean ± standard deviation.
Unpaired t tests for mean value of nasal mucosal concen-
tration in both hypotonic and isotonic suspension in the
comparison study were performed using the SAS (version
6.12) software program (SAS Institute Inc, Cary, North
Carolina).
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